Pharmaceutical Technology

FEBRUARY 15, 2023

Innovation S-curve for the pharmaceutical industry CRISPR nuclease is a key innovation area in pharmaceutical development CRISPR, which refers to clustered regularly interspaced short palindromic repeats, are bacteriophage-derived DNA sequences that had previously infected the prokaryote and are found in the genomes of bacteria and archaea.

In-Vivo 162

In-Vivo Genome Genomics Gene Editing 162

Drug Discovery World

SEPTEMBER 26, 2022

The bacteria in the intestinal tract (‘ microbiota’ ) play an important role in the success of ICI therapy, suggesting that crosstalk between the immune system and bacteria in the intestine can impact the overall anti-tumor T-cell activation status. . These adverse events often present in the intestinal tract as severe inflammation.

Bacteria 52

Bacteria Biobanking In-Vivo In-Vitro 52

Roots Analysis

JANUARY 14, 2024

Notably, biologics have higher success rates than conventional small-molecule drugs owing to lesser off-target toxicity of biologics, which is one of the key reasons of failures in small molecule drugs development. They are different from small molecules in terms of their size and complexity.

Contract Manufacturing 40

Contract Manufacturing Manufacturing Protein Bacteria 40

XTalks

NOVEMBER 3, 2023

The CRISPR-Cas9 gene editing system was first discovered to be endogenous in bacteria. Related: Intellia Gets FDA Clearance to Start First Ever Phase III Trial for an In Vivo CRISPR Drug The advisors appeared convinced that exa-cel can offer significant benefits to people with sickle cell.

Gene Therapy 59

Gene Therapy Gene Gene Editing In-Vivo 59

Roots Analysis

OCTOBER 19, 2023

Bacteria plays a crucial role in maintaining the ecosystem balance. However, there are few species of bacteria that can cause several infectious diseases ( such as strep throat, salmonellosis, tuberculosis, whooping cough ). The overuse of antibiotics has resulted in the emergence of multi-drug-resistant bacteria.

Bacteria 40

Bacteria Production In-Vivo In-Vitro 40

Drug Discovery World

OCTOBER 13, 2022

Over the two days at ExCel, 1554 delegates attended the event. Of those delegates, 75% work in drug discovery. There were 127 exhibitors, 180 posters, 40 technology speakers, 52 scientific speakers as well as a series of eight seminars focused on automation and technology which DDW organised and moderated in the dedicated Tech Theatre. .

Drugs 52

Drugs In-Vivo In-Vitro Biobanking 52

Drug Discovery World

APRIL 25, 2024

For drug discovery and development, cell lines allow researchers to test the efficacy of therapeutics before moving into in vivo studies. For instance, bacteria and yeast cell lines are easier to cultivate compared with mammalian cell lines, requiring less maintenance for the medium they are grown in.

Development 59

Development Protein In-Vivo Life Science 59